APPLICATION
ANDA208620
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-10
LATEST ACTION
2026-03-11
ROUTE
TRANSDERMAL
DOSAGE FORM
GEL, METERED
MARKETING STATUS
Prescription
Products
TESTOSTERONEPrescription
TESTOSTERONE 1.62% (20.25MG/1.25GM ACTUATION) · GEL, METERED · TRANSDERMAL
Approval history
2026-03-11Labeling · Supplement 11 · standardAP
2019-06-04Labeling · Supplement 1 · standardAP
2019-06-04Labeling · Supplement 2 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.